Jade Biosciences Q3 net loss widens to $35.1M
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Jade Biosciences, Inc. (JBIO) reported a third-quarter 2026 net loss of $35.055 million, compared with $25.175 million a year earlier. Operating expenses were $39.640 million, versus $27.401 million, and net loss per common share was $0.42 versus $0.48. Cash, cash equivalents and investments totaled $475.706 million as of September 30, 2026, compared with $336.158 million as of December 31, 2025.
Jade said it is preparing to initiate the Phase 3 EVERGREEN trial of JADE101 ahead of schedule and expects to advance JADE301 into the clinic this quarter. The company expects JADE101, JADE201 and JADE301 to be three clinical-stage programs heading into 2027. Nine-month net loss was $131.188 million, compared with $95.478 million for the same period in 2025.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Positive
- Moderate pointNet loss per common share narrowed to $0.42 from $0.48.
Negative
- Moderate pointThird-quarter net loss rose to $35.055 million from $25.175 million.
8-K Event Classification
Key Figures
Key Terms
IgA nephropathy (IgAN) medical
anti-APRIL monoclonal antibody medical
afucosylated technical
anti-BAFF-R monoclonal antibody medical
registrational study regulatory
interim data medical
Earnings Snapshot
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What was Jade Biosciences' net loss in Q3 2026?
How much did JBIO spend on research and development in Q3 2026?
AI-generated analysis. How Rhea-AI works. Not financial advice.